التفاصيل البيبلوغرافية
| العنوان: |
Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. |
| المؤلفون: |
Collier, Ai-ris Y, Yu, Jingyou, McMahan, Katherine, Liu, Jinyan, Atyeo, Caroline, Ansel, Jessica L, Fricker, Zachary P, Pavlakis, Martha, Curry, Michael P, Jacob-Dolan, Catherine, Patel, Het, Sellers, Daniel, Barrett, Julia, Rowe, Marjorie, Ahmad, Kunza, Gompers, Annika, Aguayo, Ricardo, Chandrashekar, Abishek, Alter, Galit, Hacker, Michele R |
| المصدر: |
Journal of Infectious Diseases; Apr2022, Vol. 225 Issue 7, p1124-1128, 5p |
| مستخلص: |
Individuals on immunosuppressive (IS) therapy have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and delayed viral clearance may lead to new viral variants. IS therapy reduces antibody responses following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination; however, a comprehensive assessment of vaccine immunogenicity is lacking. Here we show that IS therapy reduced neutralizing, binding, and nonneutralizing antibody functions in addition to CD4 and CD8 T-cell interferon-γ responses following COVID-19 mRNA vaccination compared to immunocompetent individuals. Moreover, IS therapy reduced cross-reactivity against SARS-CoV-2 variants. These data suggest that the standard COVID-19 mRNA vaccine regimens will likely not provide optimal protection in immunocompromised individuals. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
